KRAS and neoplasm: Consistent with these observations, we found that SAH-JGZ4 treatment of KRAS mutated A549 cells decreases KRAS activity, and inhibits tumor initiation and progression, suggesting that promoting EGFR degradation have therapeutic potential for targeting the “undrugable” KRAS mutations.